Rheumatology

Top Story

Cost savings from infliximab biosimilars ‘insufficient’ to promote use in US

Cost savings from infliximab biosimilars ‘insufficient’ to promote use in US
January 27, 2020
In the Journals

Less than 40% of patients with high RA disease activity modify treatment

January 23, 2020
Despite treat-to-target recommendations for rheumatoid arthritis, only 38% of patients with high disease activity were offered a treatment change during their most…
In the Journals

Patients with moderate PsA disease more likely to meet treatment targets with apremilast

January 23, 2020
Patients with psoriatic arthritis are more likely to achieve treatment targets, such as remission or low disease activity, with apremilast if they demonstrate moderate…
In the Journals

Neuropsychiatric events most frequent near SLE diagnosis, linked to excess mortality

January 22, 2020
Among patients with systemic lupus erythematosus, neuropsychiatric events occur most frequently around the time of the initial diagnosis, and are associated with reduced…
More Headlines »